Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
Date:3/11/2011

ber 31, 2010 includes $3.1 million related to the departure of certain employees.Condensed Consolidated Balance Sheet Data(in thousands)December 31,

2010December 31,

2009Cash, cash equivalents and short-term investments

$

80,612$

50,891Total assets

$

100,454$

55,065Total stockholders' equity

$

77,123$

24,741About Ardea Biosciences, Inc.Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases.  Lesinurad, previously called RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a once-daily, oral inhibitor of the URAT1 transporter which has completed Phase 2 clinical development.  Our next-generation URAT1 inhibitor program is currently in preclinical development.  BAY 86-9766, formerly known as RDEA119, is a potent and specific inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer being developed under a global license agreement with Bayer HealthCare AG.  BAY 86-9766 is currently in a Phase 2 study in patients with hepatocellular carcinoma in combination with sorafenib (Nexavar®; Bayer, Onyx Pharmaceuticals) and a Phase 1/2 study in patients with advanced pancreatic cancer in combination with gemcitabine.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of lesinurad, BAY 86-9766 and our other compounds and the timing and results of our precl
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
2. Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting
3. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
4. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
5. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
6. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
7. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
8. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
9. Ardea Biosciences to Present at Two Upcoming Investor Conferences
10. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
11. Ardea Biosciences Prices Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... treated and managed with the use of special anti-vascular endothelial growth factor agents ... many more patients, currently does not have a scientific protocol for the many ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cqsxmg/gene_therapy ... report "Gene Therapy - Technologies, Markets and Companies" ... gene therapy are difficult to estimate as there is ... marketed in China since 2004. ... The estimates are based on epidemiology of diseases to ...
(Date:9/2/2015)... 2, 2015 Biovista Inc. is ... the 2015 BeHEARD science challenge, a global competition hosted ... researchers, access to the latest life science innovations and ... and pathway analytics capability to support Steven Laffoon ... the study of Niemann-Pick Disease Type A (NPA), a ...
(Date:9/2/2015)... R.I. , Sept. 2, 2015  Neurotech ... been enrolled in the multicenter Phase 2 clinical ... the long-term treatment of recurrent subfoveal choroidal neovascularization ... NT-503 is a unique vascular endothelial growth factor ... ECT implant. "This landmark proof-of-concept study ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4
... 2011 Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ... development of drugs for the treatment of human viral ... quarter and year ended December 31, 2010. At December ... million. Business HighlightsIDX184 Update In ...
... CSL Behring announces a special ... in conjunction with Rare Disease Day 2011 , an ... impact on people,s lives. The Dialogue spanned two ... information and ideas for patients, caregivers and healthcare providers. ...
... of biomass to fuel requires several steps: chemical pretreatment ... acid, detoxification to remove the toxic chemicals required in ... to fuels. Virginia Tech researchers have discovered an enzyme ... infused liquid biomass (hydrolysate), meaning that the detoxification step ...
Cached Biology Technology:Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 7Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 2Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 3Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 4Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 5Enzyme cocktail could eliminate a step in biofuel process 2
(Date:8/28/2015)... According to a new market ... Type (Pen & Paper Based, Hosted, Biometrics), Service, Application ... Research), Vertical and Region - Global Forecast to 2020", ... grow from USD 2.4 Billion in 2015 to USD ... Rate (CAGR) of 25.6% from 2015 to 2020. ...
(Date:8/20/2015)... The wearable technology market has traditionally ... healthy. However, wearable technology has the potential to ... improve diagnostic capabilities and therapeutic outcomes. Today, Leaf ... Technologies Conference 2015 , where Barrett Larson ... healthcare.    "Over the past decade, ...
(Date:8/18/2015)... 17, 2015 Research and Markets ( ... "Global Biometric Authentication & Identification Market: Focus ... Forecast, 2015-2020" report to their offering. ... systems market is expected to grow at an ... and generate over $25 billion (approximately) by 2020 ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... commonly cultivated cacao plant in the world is revealed ... Researchers have utilised high quality DNA sequences to demonstrate the ... can lead to higher yielding cocoa plants that still produce better ... cacao tree ( Theobroma cacao L. ), but ...
... Plymouth University, and the Universidad Federal da Bahia in ... diversity and density of coral colonies off the coast ... El Nio event of 1997-98, creating an opportunity for ... major environmental incident of this nature can have on ...
... ecology has centered on the role of microbes in ... print in the journal Applied and Environmental Microbiology ... Australia, and collaborators show how changes in the populations ... at ecosystem levels. "Ecological theories developed for ...
Cached Biology News:Genome hints at markers for higher-producing, better-tasting chocolate 2Catastrophic climatic events leave corals facing a decade-long fight for recovery 2
More cell-permeant than acridine orange....
HistoScan HRP Kit Universal Goat Kit...
4',6-Diamidino-2-phenylindole dihydrochloride...
...
Biology Products: